TY - JOUR
T1 - Diabetes screening
T2 - Detection and application of saliva 1,5-anhydroglucitol by liquid chromatography-mass spectrometry
AU - Jian, Chaohui
AU - Zhao, Aihua
AU - Ma, Xiaojing
AU - Ge, Kun
AU - Lu, Wei
AU - Zhu, Wei
AU - Wang, Yufei
AU - Zhou, Jian
AU - JIA, Wei
AU - Bao, Yuqian
N1 - Funding Information:
Financial Support: This work was supported by the
Funding Information:
This work was supported by the Shanghai United Developing Technology Project of Municipal Hospitals (SHDC12016108) and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161430).*%blankline%*
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Context: Unlike other commonly used invasive blood glucose-monitoring methods, salivadetection prevents patients from suffering physical uneasiness. However, there are few studieson saliva 1,5-anhydroglucitol (1,5-AG) in patients with diabetes mellitus (DM).Objective: This study aimed to evaluate the effectiveness of saliva 1,5-AG in diabetes screeningin a Chinese population.Design and Participants: This was a population-based cross-sectional study. A total of 641subjects without a valid diabetic history were recruited from September 2018 to June 2019.Saliva 1,5-AG was measured with liquid chromatography-mass spectrometry.Main outcome measures: DM was defined per American Diabetes Association criteria. Theefficiency of saliva 1,5-AG for diabetes screening was analyzed by receiver operating characteristiccurves, and the optimal cutoff point was determined according to the Youden index.Results: Saliva 1,5-AG levels in subjects with DM were lower than those in subjects who didnot have DM (both P <.05). Saliva 1,5-AG was positively correlated with serum 1,5-AG andnegatively correlated with blood glucose and glycated hemoglobin (HbA1c) (all P <.05). Theoptimal cutoff points of saliva 1,5-AG0 and 1,5-AG120 for diabetes screening were 0.436 μ g/mL (sensitivity: 63.58%, specificity: 60.61%) and 0.438 μ g/mL (sensitivity: 62.25%, specificity:60.41%), respectively. Fasting plasma glucose (FPG) combined with fasting saliva 1,5-AG reducedthe proportion of people who required an oral glucose tolerance test by 47.22% compared withFPG alone.Conclusion: Saliva 1,5-AG combined with FPG or HbA1c improved the efficiency of diabetesscreening. Saliva 1,5-AG is robust in nonfasting measurements and a noninvasive andconvenient tool for diabetes screening.
AB - Context: Unlike other commonly used invasive blood glucose-monitoring methods, salivadetection prevents patients from suffering physical uneasiness. However, there are few studieson saliva 1,5-anhydroglucitol (1,5-AG) in patients with diabetes mellitus (DM).Objective: This study aimed to evaluate the effectiveness of saliva 1,5-AG in diabetes screeningin a Chinese population.Design and Participants: This was a population-based cross-sectional study. A total of 641subjects without a valid diabetic history were recruited from September 2018 to June 2019.Saliva 1,5-AG was measured with liquid chromatography-mass spectrometry.Main outcome measures: DM was defined per American Diabetes Association criteria. Theefficiency of saliva 1,5-AG for diabetes screening was analyzed by receiver operating characteristiccurves, and the optimal cutoff point was determined according to the Youden index.Results: Saliva 1,5-AG levels in subjects with DM were lower than those in subjects who didnot have DM (both P <.05). Saliva 1,5-AG was positively correlated with serum 1,5-AG andnegatively correlated with blood glucose and glycated hemoglobin (HbA1c) (all P <.05). Theoptimal cutoff points of saliva 1,5-AG0 and 1,5-AG120 for diabetes screening were 0.436 μ g/mL (sensitivity: 63.58%, specificity: 60.61%) and 0.438 μ g/mL (sensitivity: 62.25%, specificity:60.41%), respectively. Fasting plasma glucose (FPG) combined with fasting saliva 1,5-AG reducedthe proportion of people who required an oral glucose tolerance test by 47.22% compared withFPG alone.Conclusion: Saliva 1,5-AG combined with FPG or HbA1c improved the efficiency of diabetesscreening. Saliva 1,5-AG is robust in nonfasting measurements and a noninvasive andconvenient tool for diabetes screening.
KW - 1,5-anhydroglucitol
KW - Diabetes screening
KW - Liquid chromatography-mass spectrometry
KW - Saliva determination
UR - http://www.scopus.com/inward/record.url?scp=85086126630&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgaa114
DO - 10.1210/clinem/dgaa114
M3 - Journal article
C2 - 32170297
AN - SCOPUS:85086126630
SN - 0021-972X
VL - 105
SP - 1759
EP - 1769
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 6
ER -
